Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 27 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have participated in previous (specific) Phase 3 trials of Tanezumab in osteoarthritis
You may not be if
Willing to comply with scheduled visits and treatment plan Is medically fit to participate in the trial in the judgement of the Investigator
Clareo Health | Extension Study Of Tanezumab In Osteoarthritis
